Clinical Trials
12 trialsNCT07428616 2026-05-27
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Recruiting
NCT04305470 2026-05-18
MEN-301
NX Development Corp
Phase 3 Completed
NCT05636618 2026-05-14
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT06668987 2026-05-11
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Heron Neutron Medical Corp.
Phase 1/2 Completed
NCT07533942 2026-04-16
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT06752096 2026-01-16
Robot-Assisted Neurovascular Intervention
Navigantis Inc.
Phase NA Recruiting
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT03936426 2020-04-20
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEâ„¢
Clarity Pharmaceuticals Ltd
Phase 1/2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed